The Phase 3 trial was designed to assess the effect of evinacumab on LDL cholesterol
and other lipid-related endpoints.
After a median follow-up of 26 months, the incidence of the study's primary endpoint (cardiovascular death, MI stroke, hospitalization for unstable angina, or coronary revascularization) dropped by a statistically significant 15% in patients with an achieved LDL cholesterol
of 20-49 mg/dl, compared with patients whose four weeks LDL cholesterol
was at or above 100mg/dl (primarily patients randomized to the study's control arm), by 24% in all patients with LDL cholesterol
less than 20 mg/dl and by 31% in the 2% of patients whose LDL cholesterol
levels fell below 10 mg/dl.
In order to prevent LDL cholesterol
from reaching high levels in the blood, specialists advise people to adhere to diets that promote high HDL and low LDL cholesterol
The TNT trial randomized more than 10,000 subjects with known coronary artery disease and a baseline LDL cholesterol
level below 130 mg/dL to receive either 10 or 80 mg/day of atorvastatin, with fasting lipids measured in a central laboratory at 3 and 12 months, then annually.
Among 25,982 FOURIER patients with a measured LDL cholesterol
level after 4 weeks on treatment and no study event as of then, 31% had their LDL cholesterol
cut to 20-49 mg/dL, 8% achieved a LDL cholesterol
level of 10-19 mg/dL, and 2% reached a remarkable LDL cholesterol
level of below 10 mg/dL, as low as herbivores such as rabbits and deer.
The researchers then examined the association between female sex and achieving an LDL cholesterol
level of less than 70 mg/dl in patients at very high risk of a cardiovascular event.
With both types of therapies, every 1 millimole per liter (39 milligrams per deciliter) reduction in LDL cholesterol
represented a 23 percent decrease in the risk of major cardiovascular events, the team reports.
If you double the dose to 20 mg, the average accompanying drop in LDL cholesterol
is about 40 percent.
In this study, we tested the hypothesis that extreme concentrations of nonfasting remnant and LDL cholesterol
are equal contributors to risk of IHD, MI, and all-cause mortality.
Statin drugs, which include rosuvastatin (Crestor), atorvastatin (Lipitor), and simvastatin (Zocor), are commonly prescribed for patients who have already had a cardiovascular event, such as a heart attack or stroke, and they also are given to patients who are at high risk of these events due to elevated LDL cholesterol
Research shows that people with HIV infection have a twice higher heart attack rate than people without HIV.(2) Researchers who conducted this new study of hypertension and LDL cholesterol
(sometimes called "bad cholesterol") suggested three reasons why people with HIV have a higher cardiovascular disease rate than people without HIV: